“Adalimumab Safety and Effectiveness in Korean Patients with Intestinal Behçet’s Disease: Disease Duration Impacts Adverse Reactions”

https://pubmed.ncbi.nlm.nih.gov/38114956

This study found that adalimumab is a safe and effective treatment for intestinal Behçet’s disease in Korean patients, with a longer disease duration associated with decreased adverse drug reactions.